Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ACP-044 for Acute Postoperative Pain Following Orthopedic Surgery (Bunionectomy)

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ACP-044 for Acute Postoperative Pain Following Orthopedic Surgery (Bunionectomy)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CT 044 (Primary)
  • Indications Pain; Postoperative pain
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors Acadia Pharmaceuticals

    • Most Recent Events

    • 05 May 2022 Status changed from active, no longer recruiting to completed.
    • 18 Apr 2022 Results published in an Acadia Pharmaceuticals Media Release.
    • 18 Apr 2022 Primary endpoint (Mean area under the curve (AUC) of the Numeric Rating Scale (NRS) of pain intensity scores from time 0 (when first dose on Day 1 is administered) through 24 hours for ACP-044) has not been met, according to an Acadia Pharmaceuticals media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top